There's a scholarly accord that in specific paclitaxel-resistant serous ovarian cancer samples, miR-9 expression was diminished, and intriguingly, RAB34 was pinpointed as its direct influencer [37]. This evidence concerns the gene RAB34 and ovarian serous adenocarcinoma.